A Case Study to Address a Gap in the Device-to-Vial Interface Stopper Push-in by Chemo Spikes

References

1. 1.↵
   1. Falck K.,
   2. Gröhn P.,
   3. Sorsa M.,
   4. Vainio H.,
   5. Heinonen E.,
   6. Holsti L. R.

   Mutagenicity in Urine of Nurses Handling Cytostatic Drugs. Lancet 1979, 1 (8128), 1250–1251.

   OpenUrlPubMedWeb of Science
2. 2.↵
   1. Valanis B. G.,
   2. Vollmer W. M.,
   3. Labuhn K. T.,
   4. Glass A. G.

   Acute Symptoms Associated with Antineoplastic Drug Handling Among Nurses. Cancer Nurs. 1993, 16 (4), 288–295.

   OpenUrlPubMedWeb of Science
3. 3.↵
   1. McDiarmid M.,
   2. Egan T.

   Acute Occupational Exposure to Antineoplastic Agents. J. Occup. Med. 1988, 30, 984–987.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Valanis B. G.,
   2. Vollmer W. M.,
   3. Labuhn K. T.,
   4. Glass A. G.

   Association of Antineoplastic Drug Handling with Acute Adverse Effects in Pharmacy Personnel. Am. J. Hosp. Pharm. 1993, 50, 455–462.

   OpenUrlAbstract
5. 5.↵
   1. Valanis B.,
   2. Vollmer W.,
   3. Labuhn K.,
   4. Glass A.

   Occupational Exposure to Antineoplastic Agents and Self-Reported Infertility Among Nurses and Pharmacists. J. Occup. Environ. Med. 1997, 39 (6), 574–580.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Skov T.,
   2. Maarup B.,
   3. Olsen J.,
   4. Rorth M.,
   5. Winthereik H.,
   6. Lynge E.

   Leukaemia and Reproductive Outcomes Among Nurses Handling Antineoplastic Drugs. Br. J. Indust. Med. 1992, 49 (12), 855–861.

   OpenUrlPubMedWeb of Science
7. 7.↵
   1. Hemminki K.,
   2. Kyyronen P.,
   3. Lindbohm M. L.

   Spontaneous Abortions and Malformations in the Offspring of Nurses Exposed to Anaesthetic Gases, Cytostatic Drugs, and Other Potential Hazards in Hospitals, Based on Registered Information of Outcome. J. Epidemiol Community Health 1985, 39 (2), 141–147.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Skov T.,
   2. Lynge E.,
   3. Maarup B.,
   4. Olsen J.,
   5. Rorth M.,
   6. Winthereik K.

   Risks for Physicians Handling Antineoplastic Drugs. Lancet 1990, 336 (8728), 1446.

   OpenUrlPubMedWeb of Science
9. 9.↵
   1. Sessink P. J. M.,
   2. Rolf M. E.,
   3. Ryden N. S.

   Evaluation of the Phaseal Hazardous Drug Containment System. Hosp. Pharm. 1999, 34, 1311 – 1317.

   OpenUrl
10. 10.↵
    1. Connor T. H.,
    2. Anderson R. W.,
    3. Sessink P. J.,
    4. Spivey S. M.

    Effectiveness of a Closed-System Device in Containing Surface Contamination with Cyclophosphamide and Ifosfamide in an IV Admixture Area. Am. J. Health. Syst. Pharm. 2002, 59 (1), 68–72.

    OpenUrlFREE Full Text
11. 11.↵
    1. Spivey S. M.,
    2. Connor T. H.

    Determining Sources of Workplace Contamination with Antineoplastic Drugs and Comparing Conventional IV Preparation with a Closed System. Hosp. Pharm. 2003, 38 (2), 135–139.

    OpenUrl
12. 12.↵
    1. Wick C.,
    2. Slawson M. H.,
    3. Jorgenson J. A.,
    4. Tyler L. S.

    Using a Closed-System Protective Device to Reduce Personnel Exposure to Antineoplastic Agents. Am. J. Health. Syst. Pharm. 2003, 60 (22), 2314–2320.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    Center for Disease Control and Prevention. National Institute for Occupational Safety and Health. Preventing Occupational Exposure to Antineoplastic and Other Hazardous Drugs in Health Care Settings. http://www.cdc.gov/noish/docs/2004-165/pdfs/2004-165.pdf
14. 14.↵
    US Pharmacopeial Convention. General Chapter <800> Hazardous Drugs – Handling in Healthcare Settings. http://www.usp.org/usp-nf/notices/componding-notice
15. 15.↵
    1. Firouzan M.

    The evolution of the CSTD. Pharmacy Purchasing & Products, 2 2015, S1–S12.
16. 16.↵
    ISO 22413: 2010, Transfer sets for pharmaceutical preparations – Requirements and methods, second edition.
17. 17.↵
    ISO 8536-2:2010, Infusion equipment for medical use – Part 2: Closure for infusion bottle.